Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation

BMC Clinical Pharmacology

Volumn 10, Issue , 2010, Pages

  Liedert, Bernd ^a   Forssmann, Ulf ^a,b   Wolna, Peter ^a   Golob, Michaela ^a   Kovar, Andreas ^a  

^a MERCK KGAA   (Germany)

^b Merck Serono GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; SOMATOSTATIN; RECOMBINANT PROTEIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FREEZE DRYING; GROWTH HORMONE RELEASE; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREMOR; VOMITING; ADOLESCENT; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG TOLERANCE; DRUG TOXICITY; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; FREEZE DRYING; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 77957992609     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-10-14     Document Type: Article

References (16)

1. Bercu BB, Murray FT, Frasier SD, Rudlin C, O'Dea LS, Brentzel J, Hanson B, Landy H. Long-term therapy with recombinant human growth hormone (Saizen) in children with idiopathic and organic growth hormone deficiency. Endocrine 2001, 15:43-49. 10.1385/ENDO:15:1:043, 11572324.
2. Blethen SL, O'Brien F, Reinhart R. An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection]. Pediatr Endocrinol Rev 2005, 2(Suppl 3):324-326.
3. Desrosiers P, O'Brien F, Blethen S. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005, 2(Suppl 3):327-331.
4. Pitukcheewanont P, Desrosiers P, Steelman J, Rapaport R, Fuqua JS, Kreher NC, Hamlett A. Issues and trends in pediatric growth hormone therapy-an update from the GHMonitor observational registry. Pediatr Endocrinol Rev 2008, 5(Suppl 2):702-707.
5. Plotnick L, Rapaport R, Desrosiers P, Fuqua JS. Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen). Pediatr Endocrinol Rev 2009, 6(Suppl 2):278-282.
6. Saenger P, Pescovitz OH, Bercu BB, Murray FT, Landy H, Brentzel J, O'Dea L, Hanson B, Howard C, Reiter EO, . Geref International Study Group Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone. Endocrine 2001, 15:51-56. 10.1385/ENDO:15:1:051, 11572326, Geref International Study Group.
7. Simon D, Fjellestad-Paulsen A, Crabbé R, Czernichow P. Intermittent recombinant growth hormone (Saizen) treatment in short children born small for gestational age: results of two different treatment regimens on growth parameters after 4 years. Endocrine Abstracts 2004, 8:55.
8. Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK, Acerini CL. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008, 93:147-148. 10.1136/adc.2006.114249, 17768149.
9. FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Center for Drug Evaluation and Research 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf
10. FDA Code of Federal Regulations, Title 21, Part 320: Bioavailability and Bioequivalence requirements. 2008, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=320
11. Guidance on the Investigation of Bioequivalence. EMA 2008, http://www.emea.europa.eu/pdfs/human/qwp/140198enrev1.pdf
12. Saizen SPC. 2006, http://www.emc.medicines.org
13. Brearley C, Priestley A, Leighton-Scott J, Christen M. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol 2007, 7:10. 10.1186/1472-6904-7-10, 2093927, 17922895.
14. Mullis PE, Pal BR, Matthews DR, Hindmarsh PC, Phillips PE, Dunger DB. Half-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin-dependent) diabetes mellitus. Clin Endocrinol (Oxf) 1992, 36:255-263. 10.1111/j.1365-2265.1992.tb01441.x, 1348664.
15. Lanreotide solution for injection SPC. 2008, http://www.emc.medicines.org
16. Octreotide solution for injection SPC. 2008, http://www.emc.medicines.org